NVS: Novartis AG - Summary | Jitta

Novartis AG

NYSE:NVS

Price
$87.68
Loss Chance
41.7%
6.66JITTA SCORE
52.27%Under Jitta Line
Jitta Ranking
10 / 1,196
291 / 5,062
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (62)
Recent Business Performance (71)
Financial Strength (80)
Return to Shareholders (71)
Competitive Advantage (60)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Key Stats
Jitta Score
Jitta Line
6.66
52.27%
1.91
284.83%
2.00
180.37%
Pharmaceuticals
6.67
36.63%
3.70
73.02%
4.54
80.50%
COMPANY DESCRIPTION
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.